XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Net revenues $ 3,850 $ 3,595 $ 11,389 $ 11,041
Cost of sales 1,999 1,926 6,159 5,839
Gross profit 1,851 1,669 5,230 5,203
Research and development expenses 253 175 726 628
Selling and marketing expenses 576 539 1,726 1,716
General and administrative expenses 268 283 870 892
Intangible assets impairments 47 24 289 223
Goodwill impairment 0 0 700 745
Other assets impairments, restructuring and other items 46 36 241 282
Legal settlements and loss contingencies 314 195 1,009 2,048
Other income (9) (2) (43) (88)
Operating income (loss) 355 419 (289) (1,244)
Financial expenses, net 280 252 808 721
Income (loss) before income taxes 75 166 (1,097) (1,964)
Income taxes (benefit) (12) 107 (48) (792)
Share in (profits) losses of associated companies, net [1] 1 (1) (20)
Net income (loss) 88 58 (1,048) (1,152)
Net income (loss) attributable to non-controlling interests 8 3 (60) (21)
Net income (loss) attributable to Teva $ 80 $ 56 $ (988) $ (1,132)
Earnings (loss) per share attributable to ordinary shareholders:        
Basic $ 0.07 $ 0.05 $ (0.88) $ (1.02)
Diluted $ 0.07 $ 0.05 $ (0.88) $ (1.02)
Weighted average number of shares (in millions):        
Basic 1,121 1,111 1,119 1,109
Diluted 1,135 1,119 1,119 1,109
[1] Represents an amount less than $0.5 million.